• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
Tebubio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Drug Discovery

Immunotherapy Screening – A focus on PD-1/PD-L1/PD-L2 Pathway in drug discovery

07/07/2014 by Ali El Baya, PhD No Comments

The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory and co-stimulatory signals which are modulated by most immunotherapeutic approaches.

Therapeutic manipulation of immunopathways has lead to promising clinical results for the treatment of a number of diseases (ex. cancer, autoimmune diseases and inflammatory diseases…). Research projects in this field are rapidly evolving as scientists seek to identify the next generation of therapies.

In an earlier post on this blog, I introduced the latest advances regarding the the B7-1 : CD28 and B7-1 : CTLA4 pathways for immunotherapy screenings. Today, I’d like to focus on the PD-1/PD-L1/PD-L2 pathway.

After a brief review of the role of this pathway in immune response, let’s take a look at some of the screening tools I’ve selected (by our partner BPS Biosciences) to investigate this pathway for drug discovery applications. Interestingly, some of these tools are the first ready-to-use assay kits made available for drug discoverers to screen for inhibitors of the PD-1/PD-L1/PD-L2pathway.

Why look at PD-1/PD-L1/PD-L2 pathways in immunotherapeutics?

PD-1 is a receptor present on the surface of activated T-cells and other immune cells.  PD-1 has two ligands, PD-L1 and PD-L2, which are overexpressed in most human cancers.  Binding of PD-L1 to PD-1 negatively regulates T cell signaling and inhibits cytotoxic T-cell activity.

PD1 - PD-L1 - PD-L2

Similarly, engagement of PD-1 by PD-L2 dramatically inhibits T-cell proliferation, especially in CD4+ (T helper) cells. Therefore, this upregulation of PD-L1 and PD-L2 may allow cancers to evade the host immune system.

Neutralizing antibodies can prevent PD-L1 from binding to PD-1 or to B7-1. Blockade of PD-L1 enables the activation of T-cells, restoring their ability to detect and attack tumor cells. Therefore a number of pharmaceutical companies are actively developing monoclonal antibodies targeting PD-1 and PD-L to boost the immune system for the treatment of non-small-cell lung cancer, melanoma, and bladder, renal, and triple-negative breast cancers.

The PD-1/PD-L pathway is also a therapeutic target for chronic viral-infections (including HIV and HCV). This therapeutic appraoch is based on the observation that PD-1 expression is upregulated by virus-specific T cells and that the inhibition of this loop is hoped to decrease viral load by increasing  T cell function. Conversely, since the PD-1/PD-L interaction regulates self-tolerance and immunologic homeostasis, agonists of these proteins are promising drug targets for many autoimmune disorders including multiple sclerosis, arthritis, lupus, and type I diabetes.

The most advanced PD-1/PD-L1/PD-L2 screening reagents

These new therapeutical advances highlight the importance of reliable R&D tools in Drug discovery approaches and translation medicine programs. Access to robust research reagents covering the needs of Drug discoverers from target validation to screening (HTS or secondary) or even DMPK studies is crucial. Below, I’ve made a selection of some of the latest releases for scientists interested in the PD-1/PD-L1/PD-L2 pathway.

         #1 – PD-1  – a receptor for PD-L1

PD-1 is the receptor for PD-L1. Formation of the receptor-ligand complex leads to an inhibitory signal which reduces proliferation of CD8x T cells.

PD-1 is available as a Fc Fusion (Id. nr 71106), as a FLAG-tagged variant (Id. nr 71115), and as a Biotin labeled variant (Id. nr 71109)

        #2 – PD-L1 – a ligand for PD-1 receptor

PL-L1 is one of the ligands for PD-1, which plays a role in surpressing the immune response especially during pregnancy, tissue allografts, autoimmune diseases and diseases such as Hepatitis.

PL-L1 is available as a non labeled variant (Id. nr 71104) and a Biotin-labeled variant (Id. nr 71105).

        #3 – PD-L2 –  aligand for PD-2 receptor

PL-L2 is another ligand for PD-1 which, upon complex formation T cell proliferation, especially of CD4+ (T helper) cells, is dramatically decreased.

PL-L2 is available as a non labeled variant (Id. nr 71107) and a Biotin-labeled variant (Id. nr 71108).

        #4 – PD1-neutralizing antibody

This antibody (Id. nr 71120) can be used as a control inhibitor using the PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit (see below).

Ready-to-use PD-1/PD-L1/PD-L2 screening assay kits

Recently, BPS Biosciences have released 3 unique ready-to-use assay kits to screen and profile inhibitors for the PD-1/PD-L1/PD-L2 signaling pathways

PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit (Id. nr 72003)

PD-1:PD-L2[Biotinylated] Inhibitor Screening Assay Kit Id. nr 72004)

Both are 96-well format assay kits and come with biotinylated PD-L1 or PD-L2, purified PD-1,  streptavidin labeled HRP for 100 binding reactions.

PD-L1-PD-1 Interaction measured by Luminescence

Typical data obtained with the BPS’ Ready-to-use Inhibitor Screening assays.

PD-L2 Inhibitor Screening Assay Kit (Id. nr 72006).

This 96-well format assay kits comes with biotinylated PD-1, purified PD-L2,  streptavidin labeled HRP  for 100 binding reactions.

Looking for PD-1/PD-L1/PD-L2 testings?

Choosing the right reagents or screening kits to raise the value of your compounds of interest by looking to PD-1/PD-L1/PD-L2 pathway can be challenging.

Research tools reviewed in this second post (belonging to a series of 3 posts dedicated to  Immunotherapy screening) will definitely help you there. Otherwise, you can simply contact me with the form below.

Recently released Immunotherapy Screening posts on the blog “being bio-reactive”:

  • Immunotherapy Screening – Part 1:  B7-1:CD28 and B7-1:CTLA4 Pathways

Upcoming Immunotherapy Screening posts on the blog “being bio-reactive”:

  • Immunotherapy Screening – Part 3:  BLTA:HVEM and CD47:SIRPalpha Pathways
Drug Discovery

Immunotherapy Screening – B7-1 / CD28 and B7-1 / CTLA4 Pathways in Drug Discovery

01/07/2014 by Ali El Baya, PhD No Comments

The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory and co-stimulatory signals and most immunotherapies modulate these signals.

Therapeutic manipulation of immunopathways has lead to promising clinical results for the treatment of a number of diseases such as cancer, autoimmune diseases and inflammatory diseases. Research in this field is rapidly evolving as scientists seek to identify the next generation of therapies.

In the first post of a series of three,  I will describe the B7-1 : CD28 and B7-1 : CTLA4 pathways and summarize the portfolio of tools currently available to researchers to investigate these pathways. In fact, these are the first kits on the market to screen for inhibitors of these pathways.

Continue reading
Drug Discovery, Supplying Discovery Tools

How to measure Calcium in cell based assays?

30/06/2014 by Ali El Baya, PhD No Comments

In Pharma screening departments there is a strong need for Ca2+ measurement methods.

Why is this?

GPCR - Calcium mobilisation

GPCRs (G Protein Coupled Receptors) are still major targets of pharmaceutical screenings.

Around 30-40% of all drugs on the market are directed against GPCRs.

Drugs have an impact on the GPCR activity and thus the downstream signal transduction cascade. GPCRs are linked to the activity of heterotrimeric G proteins which consist of alpha, beta and gamma subunits. These G proteins have an effect on PhosphoLipase C (PLC) which leads to the release of Inositol Phosphate 3 (IP3) which finally leads to intracellular Ca2+ mobilization (release from the endoplasmic reticulum ) – Ca2+ finally has effect on a number of further cellular processes.

The fact that GPCR activation always leads to Ca2+mobilization is commonly used to indirectly measure the impact of compounds/drug candicates on GPCRs.

Hence the need for Ca2+ measurement methods, such as the following…

Continue reading
Cell Biology and Signalling

Is there a link between members of Rho family of small G proteins and reactive oxygen species?

25/06/2014 by Ali El Baya, PhD No Comments

Redox schematic representation and crosstalk between GTPase pathwaysBoth ROS (Reactive Oxygen Species) and RNS (Reactive Nitrogen Species) on the one hand, and the small G proteins belonging to the Rho family on the other hand, are key regulators in various signal transduction pathways.

More recently it has been suggested that crosstalk between reactive species and Rho GTPases plays a crucial role in some of their physiological functions. Furthermore, these crosstalk events have been linked to pathological processes, e.g. lung injury and cancer.

Our partner Cytoskeleton Inc.  has summarized recent findings in the newsletter Rho GTPases and Reactive Oxygen Species: Crosstalk and Feedback. Let’s take a look at what’s available for research in this area.

Continue reading
Page 33 of 33« First...1020«30313233

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • From RUO to IVD - the acronym guide to reagents' intended use
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
My Tweets

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com

 

Loading Comments...